BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kondo M, Numata K, Hara K, Nozaki A, Fukuda H, Chuma M, Maeda S, Tanaka K. Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression. Gastroenterol Res Pract 2017;2017:5728946. [PMID: 28717362 DOI: 10.1155/2017/5728946] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Sawada K, Saitho Y, Hayashi H, Hasebe T, Nakajima S, Ikuta K, Fujiya M, Okumura T. Skeletal muscle mass is associated with toxicity, treatment tolerability, and additional or subsequent therapies in patients with hepatocellular carcinoma receiving sorafenib treatment. JGH Open 2019;3:329-37. [PMID: 31406927 DOI: 10.1002/jgh3.12167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Heo YA, Syed YY. Regorafenib: A Review in Hepatocellular Carcinoma. Drugs 2018;78:951-8. [PMID: 29915898 DOI: 10.1007/s40265-018-0932-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
3 Fung AS, Tam VC, Meyers DE, Sim HW, Knox JJ, Zaborska V, Davies J, Ko YJ, Batuyong E, Samawi H, Cheung WY, Lee-Ying R. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab. Cancer Med 2020;9:4640-7. [PMID: 32378799 DOI: 10.1002/cam4.3116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
4 Kumar P, Gautam AK, Kumar U, Bhadauria AS, Singh AK, Kumar D, Mahata T, Maity B, Bera H, Saha S. Mechanistic exploration of the activities of poly(lactic-co-glycolic acid)-loaded nanoparticles of betulinic acid against hepatocellular carcinoma at cellular and molecular levels. Arch Physiol Biochem 2020;:1-13. [PMID: 32141770 DOI: 10.1080/13813455.2020.1733024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Singh AK, Bhadauria AS, Kumar U, Raj V, Maurya V, Kumar D, Maity B, Prakash A, De A, Samanta A, Saha S. Novel fused oxazepino-indoles (FOIs) attenuate liver carcinogenesis via IL-6/JAK2/STAT3 signaling blockade as evidenced through data-based mathematical modeling. Life Sciences 2018;201:161-72. [DOI: 10.1016/j.lfs.2018.02.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Kondo M, Morimoto M, Kobayashi S, Ohkawa S, Hidaka H, Nakazawa T, Aikata H, Hatanaka T, Takizawa D, Matsunaga K, Okuse C, Suzuki M, Taguri M, Ishibashi T, Numata K, Maeda S, Tanaka K. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial. BMC Cancer 2019;19:954. [PMID: 31615466 DOI: 10.1186/s12885-019-6198-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
7 Maurya V, Kumar P, Chakraborti S, Singh AK, Bhadauria AS, Kumar U, Kumar D, Pramanik A, Saha B, Kumar R V, Gosipatala SB, Bhattachariya B, Maity B, Saha S. Zolmitriptan attenuates hepatocellular carcinoma via activation of caspase mediated apoptosis. Chemico-Biological Interactions 2019;308:120-9. [DOI: 10.1016/j.cbi.2019.05.033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 Saeki I, Yamasaki T, Yamauchi Y, Takami T, Kawaoka T, Uchikawa S, Hiramatsu A, Aikata H, Kawano R, Kobayashi K, Kondo T, Ogasawara S, Chiba T, Chayama K, Kato N, Sakaida I. Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2247. [PMID: 34067075 DOI: 10.3390/cancers13092247] [Reference Citation Analysis]